I think the report is good - nearly half the MC in cash backing, 10 private payer meetings coming, record patient tests, 34% ave licence fee increase across the renewed 38 units.
Also they keep winning against private payors - in the end cheaper for the payors not to have to review endless numbers of cases, and cheaper for IPD too, and better for patients. This does not look like a business that will fail to gain reimbursement. However that will be the next catalyst.
IPD Price at posting:
5.4¢ Sentiment: Buy Disclosure: Held
